Kyowa Pharmaceutical and FRONTEO conclude a partnership agreement regarding the development and sale of new medical devices that utilize AI to support dementia diagnosis

Home » corporate » News » 2020 » Kyowa Pharmaceutical and FRONTEO conclude a partnership agreement regarding the development and sale of new medical devices that utilize AI to support dementia diagnosis
2020.06.03 Press release

--To the press -

Kyowa Pharmaceutical and FRONTEO conclude a partnership agreement regarding the development and sale of new medical devices that utilize AI to support dementia diagnosis

 Kyowa Pharmaceutical Industry Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture, President: Noriaki Tsunoda, hereinafter Kyowa Pharmaceutical Industry Co., Ltd.) and FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) We have signed a business alliance agreement regarding the AI ​​system (medical equipment) that supports dementia diagnosis.

 

 Since the basic agreement in February this year, Kyowa Pharmaceutical and FRONTEO have been discussing the construction of a new development and sales system, such as research, development, marketing, and sales of this system.Under this agreement, we will strive to maximize the value of this system by utilizing Kyowa Yakuhin's experience and sales capabilities in the psychiatric field and FRONTEO's AI technology and digital knowledge.In consideration of the alliance, Kyowa will pay FRONTEO a lump sum contract payment, development, sales milestones and royalties based on sales, and FRONTEO will supply Kyowa with the final product.

 


 The dementia diagnosis support AI system utilizes FRONTEO's original natural language analysis AI "Concept Encoder" to determine the presence or absence of cognitive dysfunction from a conversation between a patient and a doctor for about 5 to 10 minutes. is. As of 2020, there are more than 600 million dementia patients in Japan※ 1, The number of elderly people who are said to have a high risk of developing dementia is about 1,800 million※ 2For Japan, which will face a super-aging society for a long time in the future, dementia countermeasures will be a national issue.To address this issue, this system provides (XNUMX) reduction of the physical and psychological burden on both patients and medical staff, (XNUMX) early detection of dementia and efficiency of medical care, and (XNUMX) telemedicine and other digital medical care. We believe that we can contribute from the perspective of progress.In addition, this system is the world's first system that can support the diagnosis of dementia through natural conversations rather than specialized conversations and interviews, and as a medical device that utilizes linguistic artificial intelligence (AI). We are aiming to obtain early approval in Japan ahead of the rest of the world.

 

 

* 1 From the Ministry of Health, Labor and Welfare "Future Estimates for People with Dementia"

https://www.mhlw.go.jp/content/000524702.pdf

* 2 From the Cabinet Office "White Paper on Aging Society"

https://www8.cao.go.jp/kourei/whitepaper/index-w.html

 

concept encoderabout URL: https://lifescience.fronteo.com/

"Concept Encoder (concept encoder)®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

 

About Kyowa Pharmaceutical Industry Co., Ltd. URL: http://www.kyowayakuhin.co.jp/

Kyowa Pharmaceutical Industry Co., Ltd. (Kyowa Pharmaceutical Industry Co., Ltd.) was founded in 1954 and has expanded its business centered on generic drugs under the "Amel" brand, focusing on the CNS (central nervous system) area.In addition to generic drugs, long-listed products, which were transferred from Shionogi in 2016, will be sold as new drugs for the treatment of depressive symptoms of bipolar disorder, which was commissioned by Astellas Pharma in 2017. We are also promoting further development in the CNS area by comprehensively providing new drugs.

Kyowa Yakuhin has a new management vision of "Aiming to be a CNS Total Solution Company," and through the provision of products and services that go beyond pharmaceuticals, mainly in the CNS domain, patients and their families, medical professionals, and society. We will take on various challenges with the aim of becoming a company that can contribute to. Sales for the year ended March 2019, 3 were 282 billion yen.

 

FRONTEOabout URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".®(Kibit) "and" concept encoder®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).

 

[Contact from the press]

Public Relations Officer, FRONTEO Inc. Segawa

 Email: pr_contact@fronteo.com

[Inquiries about Life Science AI Business]

Life Science AI Business Department, FRONTEO, Inc.

 Email: fhc_contact@fronteo.com